Literature DB >> 789082

Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man.

J F De Plaen, A Amery, T Reybrouck.   

Abstract

The comparative potency of two beta-blockers, propranolol and atenolol, in the inhibition of exercise tachycardia and isoproterenol-tachycardia has been studied in two groups of hypertensive patients, using oral doses which were increased weekly. A linear correlation was observed between the reduction in exercise tachycardia and the dose of each drug, up to a daily dose of propranolol 480 mg and atenolol 600 mg. Propranolol was slightly (0.7/1) more potent in decreasing maximal exercise tachycardia than atenolol when tested in low doses (below 100 mg); at higher doses (480 mg) no differences were found. However, atenolol was 10 times less potent than propranolol in blocking isoprenaline-induced tachycardia, which seems to be related to the cardioselectivity of atenolol.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 789082     DOI: 10.1007/bf00565617

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  An investigation into the cardiac and pulmonary beta-adrenoceptor blocking activity of ICI 66,082 in man.

Authors:  G E Marlin; C R Kumana; C M Kaye; D M Smith; P Turner
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

2.  Predictive value of various parameters for the antihypertensive effect of the beta blocker ICI 66,082 (1).

Authors:  J Meekers; A Missotten; R Fagard; D Demuynck; C Harvengt; P Pas; L Billiet; A Amery
Journal:  Arch Int Pharmacodyn Ther       Date:  1975-02

3.  A new test of the degree of adrenergic beta receptor blockade.

Authors:  J D Fitzgerald
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1970-12

4.  Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise.

Authors:  I Brick; K J Hutchison; D G McDevitt; I C Roddie; R G Shanks
Journal:  Br J Pharmacol       Date:  1968-09       Impact factor: 8.739

5.  Intravenously administered isoproterenol sulfate dose-response curves in man.

Authors:  C F George; M E Conolly; T Fenyvesi; R Briant; C T Dollery
Journal:  Arch Intern Med       Date:  1972-09

6.  Initial clinical experience with I.C.I. 66.082, a new beta-adrenergic blocking agent, in hypertension.

Authors:  L Hansson; H Aberg; S Jameson; B Karlberg; R Malmcrona
Journal:  Acta Med Scand       Date:  1973-12

7.  Preliminary report on the haemodynamic response of hypertensive patients treated with a beta blocker (ICI 66082).

Authors:  A Amery; L Billiet; J V Joossens; J Meekers; T Reybrouck; W Van Mieghem
Journal:  Acta Clin Belg       Date:  1973       Impact factor: 1.264

8.  Effect of a new beta-adrenergic blocking agent, ICI 66o82, on exercise haemodynamics and airway resistance in angina pectoris.

Authors:  H Aström; H Vallin
Journal:  Br Heart J       Date:  1974-12

9.  Proceedings: Preliminary observations on the human pharmacology of I.C.I. 66082 in normal volunteers.

Authors:  B R Graham; D W Littlejohns; B N Prichard; B Scales; P Southorn
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

10.  Controlled study of atenolol in treatment of hypertension.

Authors:  L Hansson; H Aberg; B E Karlberg; A Westerlund
Journal:  Br Med J       Date:  1975-05-17
View more
  15 in total

1.  Relative activity of atenolol and metoprolol.

Authors:  M B Comerford; E M Besterman
Journal:  Br Med J       Date:  1977-07-23

2.  Differential cardiovascular effects of propranolol, atenolol, and pindolol measured by impedance cardiography.

Authors:  S H Thomas; R C Cooper; M Ekwuru; S Fletcher; J Gilbody; T S Husseyin; M Ishaque; R Jagathesan; G Reddy; S E Smith
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Haemodynamic response to graded exercise during chronic beta-adrenergic blockade with bunitrolol, an agent with intrinsic sympathomimetic activity.

Authors:  T Reybrouck; A Amery; R Fagard; L Billiet
Journal:  Eur J Clin Pharmacol       Date:  1977-12-16       Impact factor: 2.953

4.  Blockade of isoprenaline-induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol.

Authors:  H H Harms; L Gooren; A J Spoelstra; C Hesse; L Verschoor
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

Review 5.  Exercise performance and beta-blockade.

Authors:  P A Tesch
Journal:  Sports Med       Date:  1985 Nov-Dec       Impact factor: 11.136

6.  Cardiac beta 2-adrenoceptors and the inotropic response to exercise in man.

Authors:  C Nyarko-Adomfeh
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

7.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

Review 8.  Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-06       Impact factor: 9.546

9.  Response of the systemic pulmonary circulation to labetalol at rest and during exercise.

Authors:  R Fagard; P Lijnen; A Amery
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

10.  Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers.

Authors:  P C O'Connor; M J Finch; D W Harron; P A Meredith; D G McDevitt; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.